Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $843K | $0.00 | $150K | — | $0.00 | $0.00 | $0.00 | $420K | $43.0K | $0.00 |
| Revenue growth | — | -100.0% | — | — | — | — | — | — | -89.8% | -100.0% |
| Operating income | -$14.2M | -$9.49M | -$9.55M | -$9.68M | -$10.6M | -$22.9M | -$27.7M | -$25.5M | -$12.0M | -$8.43M |
| Operating margin | -1678.5% | — | -6365.3% | — | — | — | — | -6060.2% | -27916.3% | — |
| Net income | -$11.8M | -$7.47M | -$7.29M | -$7.83M | -$8.45M | -$18.9M | -$21.2M | -$22.6M | -$11.2M | -$3.00M |
| Net margin | -1398.7% | — | -4858.7% | — | — | — | — | -5370.2% | -26074.4% | — |
| EPS (diluted) | -$3.50 | -$1.95 | -$0.62 | -$9.84 | -$3.42 | -$2.14 | -$27.24 | -$26.75 | -$502.46 | -$6.45 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.1M | -$7.48M | -$6.70M | -$9.45M | -$7.93M | -$18.5M | -$20.8M | -$16.1M | -$7.99M | -$4.77M |
| Capital expenditures | $3.00K | $13.0K | $39.0K | $10.0K | $96.0K | $27.0K | $7.00K | $6.00K | — | — |
| Free cash flow | -$10.1M | -$7.49M | -$6.74M | -$9.46M | -$8.03M | -$18.6M | -$20.8M | -$16.1M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.5M | $23.9M | $17.5M | $11.9M | $33.4M | $36.6M | $18.3M | $3.38M | $3.14M | $3.50M |
| Total assets | $19.7M | $26.0M | $19.8M | $15.3M | $36.8M | $42.6M | $28.1M | $8.80M | $4.09M | $8.19M |
| Total liabilities | $5.39M | $4.24M | $4.55M | $3.61M | $3.54M | $5.32M | $7.62M | $8.20M | $6.27M | $1.34M |
| Shareholders' equity | $14.3M | $21.8M | $15.3M | $11.7M | $33.3M | $37.7M | $15.9M | $607K | -$2.17M | $6.84M |
| Retained earnings | -$335M | -$343M | -$350M | -$358M | -$366M | -$385M | -$406M | -$428M | -$439M | -$454M |
| Shares (wtd avg diluted) | 4.26M | 12.0M | 12.5M | 860K | 3.63M | 8.93M | 11.3M | 851K | 22.3B | 2.19M |
Every figure is extracted from Bio Green Med Solution, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.